Covering Disruptive Technology Powering Business in The Digital Age

EyRIS a subsidiary of Nova MSC Berhad (“Nova MSC” or “the Company”), a leading provider of industry-focused application software and services for the healthcare sector, has secured a contract valued at RM7.13 million from JPMCnova Sdn Bhd. This milestone contract will see the rollout of the National Diabetic Retinopathy (DR) Screening Program in Brunei Darussalam.

Brunei Darussalam is one of the earliest countries in the world to strengthen its public health system by integrating a deep learning system into their national DR screening program. This follows the successful adoption of SELENA+ in Singapore and the Sultanate of Oman. The five-year project, set to commence in October 2024, will use EyRIS’ advanced AI platform, EySCAN and SELENA+ across hospitals and healthcare centres in the Sultanate.

This marks a significant step forward in Brunei’s healthcare strategy as the country confronts a growing diabetic population, currently estimated at 13.3%, which translates to approximately 40,000 citizens. With DR being the number one cause in vision impairment, a systematic approach to early detection of DR is crucial to ensure early treatment and preventing vision loss.

SELENA+, an automated deep-learning system developed in collaboration with the Singapore Eye Research Institute (SERI) and the NUS School of Computing, offers a groundbreaking solution for the early detection of diabetic retinopathy, glaucoma, and age-related macular degeneration through the analysis of colour retinal images. Classified as a medical device, SELENA+ has secured regulatory approvals in the European Union and countries such as Australia, Brazil, Malaysia, Thailand and Indonesia.

“We are proud to partner MOH, Brunei to in their quest to leverage AI technology to transform how a medical service can be delivered cost-effectively,” said Mr. Lai Teik Kin, Group CEO of Nova MSC. “The nationwide deployment of SELENA+ will streamline the entire screening process and provide instantaneous & accurate diagnoses.”

Beyond DR, EyRIS can expand AI offerings to detect systemic diseases such as chronic kidney disease, neurological disorders and cardiovascular conditions. This aligns with Nova MSC’s vision of addressing global healthcare challenges with wider access to solutions that promises to be cheaper, faster and more accurate.

The project will establish a robust National DR Screening Program across Brunei’s hospitals and healthcare centres, all connected to EyRIS’ cloud-based tele-ophthalmology platform, EySCAN. This will allow for systematic and efficient screening across the nation, driving significant cost savings and elevating the standard of care for patients.

The selection of SELENA+ in this project further cements Nova MSC’s leadership in healthcare innovation, especially in the area of 1^st stage medical diagnosis.

(0)(0)